Shattuck Labs CEO Adds Equity, Receives Warrants Linked to Clinical Milestones

Rhea-AI Filing Summary

Insider purchase and warrant grant reported for Shattuck Labs (STTK). Taylor Schreiber, the company’s Chief Executive Officer and a director, participated in a private placement that closed on August 25, 2025, acquiring 25,610 shares of common stock at $0.8677 per share and receiving accompanying warrants to buy up to 25,610 shares. After the transaction Schreiber directly owns 96,612 shares. Schreiber also holds an indirect interest of 2,610,750 shares through Houghton Capital Holdings, LLC. The warrants are exercisable until the 30th day after the issuer publicly announces specific Phase 1 clinical trial data and planned Phase 2 design.

Positive

• CEO and director participation in the private placement, indicating management alignment with the financing
• Acquisition of both common stock and warrants, providing immediate equity ownership and potential upside tied to clinical progress
• Substantial indirect ownership of 2,610,750 shares through Houghton Capital Holdings, LLC, increasing insider economic interest

Negative

• None.

Insights

Financial Analyst

TL;DR: CEO participated in a private placement, adding equity and warrants; direct stake modest, indirect stake substantial.

The transaction shows management participation in a private financing at $0.8677 per share, which aligns insider economic exposure with shareholders. The direct purchase of 25,610 shares plus detachable warrants provides both immediate equity and potential upside if clinical milestones trigger favorable valuation. The large indirect holding (2,610,750 shares) via Houghton Capital Holdings materially increases the reporting person’s overall position and is relevant when assessing alignment and insider voting influence.

Corporate Governance Expert

TL;DR: Insider purchase signals alignment; warrant exercise tied to clinical disclosure conditions creates milestone linkage.

Schreiber’s role as CEO and director combined with participation in the private placement demonstrates management commitment to financing. The warrants’ exercisability depends on public disclosure of Phase 1 dosing, receptor occupancy, safety data and Phase 2 design, linking potential dilution to clinical progress. This structure ties insider economic interest to key development milestones disclosed to the market.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schreiber Taylor

(Last) (First) (Middle)

C/O SHATTUCK LABS, INC.

500 W. 5TH STREET, SUITE 1200

(Street)

AUSTIN TX 78701

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Shattuck Labs, Inc. [ STTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/25/2025		A(1)		25,610	A	$0.8677(1)	96,612	D
Common Stock								2,610,750	I	By Houghton Capital Holdings, LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants (Right to Buy)	$1.0846	08/25/2025		A(1)		25,610		(2)	(2)	Common Stock	25,610	(1)	25,610	D

Explanation of Responses:

1. On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 25,610 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 25,610 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677.

2. The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly.

	/s/ Andrew R. Neill, Attorney-in-Fact for Taylor Schreiber	08/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Taylor Schreiber acquire in the Form 4 filing for STTK?

The filing shows acquisition of 25,610 common shares and accompanying warrants to purchase 25,610 shares at a combined price of $0.8677 per share/Warrant.

How many STTK shares does Taylor Schreiber own after the transaction?

Following the transaction Schreiber directly beneficially owns 96,612 shares and indirectly holds 2,610,750 shares through Houghton Capital Holdings, LLC.

When are the warrants exercisable according to the filing?

The warrants are exercisable any time from issuance until the 30th day after public announcement of specified Phase 1 clinical trial data and the planned Phase 2 trial design.

What price was paid in the private placement reported on the Form 4?

The combined price per share and accompanying warrant was $0.8677.

Who filed the Form 4 on behalf of Taylor Schreiber?

The Form 4 was signed and filed by Andrew R. Neill, Attorney-in-Fact for Taylor Schreiber on the filing date.